← Leaderboards
Ann Chen Wu
Harvard Pilgrim Health Care, Inc.
$7,884,984
Attributed
$9,747,077
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2009–23$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$9,747,077 · 5
By mechanism
R01$6,771,516 · 2
U01$1,791,664 · 1
K08$644,892 · 1
R21$539,005 · 1
Top collaborators
- Christine Lu3 shared
- Oguzhan Alagoz1 shared
- Harry De Koning1 shared
- Xuelin Huang1 shared
- Sandra J Lee1 shared
- Jeanne Mandelblatt1 shared
- Sylvia Katina Plevritis1 shared
- Amy Trentham-Dietz1 shared
Most similar at Harvard Pilgrim Health Care, Inc.
Same institution · by research overlap
- Christine Lu$2,783,981
Others in their field
Top investigators on “Innovation”
- David R. Weir · University Of Michigan At Ann Arbor$382,307,654
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$319,874,172
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$311,654,401
- Richard A Gibbs · Baylor College Of Medicine$300,634,418
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$271,752,220
Research focus
InnovationCaringCostPoliciesAffectAdultLifeChildhoodFutureClinical CareInsightGeneticLinkClinical TrialsGenomicsBaseFundingAreaClinical PracticeEpidemiologyInformaticsCost EffectivenessBenefits And RisksHealth Benefit
Grant awards (20)
Precision Medicine Policy and Treatment (PreEMPT) Model II$864,602
R01 · FY2023 · HD · contact PI
Comparative Modeling of Precision Breast Cancer Control Across the Translational Continuum$1,791,664
U01 · FY2022 · CA
Precision Medicine Policy and Treatment (PreEMPT) Model$516,162
R01 · FY2021 · HD · contact PI
Age-Dependent Pharmacogenomics of Asthma Treatment (ADAPT)$590,294
R01 · FY2020 · HD · contact PI
Precision Medicine Policy and Treatment (PreEMPT) Model$526,696
R01 · FY2020 · HD · contact PI
Age-Dependent Pharmacogenomics of Asthma Treatment (ADAPT)$590,294
R01 · FY2019 · HD · contact PI
Precision Medicine Policy and Treatment (PreEMPT) Model$557,558
R01 · FY2019 · HD · contact PI
Age-Dependent Pharmacogenomics of Asthma Treatment (ADAPT)$587,532
R01 · FY2018 · HD · contact PI
Precision Medicine Policy and Treatment (PreEMPT) Model$571,928
R01 · FY2018 · HD · contact PI
Age-Dependent Pharmacogenomics of Asthma Treatment (ADAPT)$659,737
R01 · FY2017 · HD · contact PI
Precision Medicine and Treatment (PreEMPT)$598,874
R01 · FY2017 · HD · contact PI
Age-Dependent Pharmacogenomics of Asthma Treatment (ADAPT)$707,839
R01 · FY2016 · HD · contact PI
Genomics-based Technologies: Access and Reimbursement Issues$211,627
R21 · FY2016 · HG
Genomics-based Technologies: Access and Reimbursement Issues$74,944
R21 · FY2016 · HG
Genomics-based Technologies: Access and Reimbursement Issues$252,434
R21 · FY2015 · HG
Effectiveness of Pharmacogenetic Testing in Asthma$129,060
K08 · FY2013 · HL · contact PI
Effectiveness of Pharmacogenetic Testing in Asthma$129,060
K08 · FY2012 · HL · contact PI
Effectiveness of Pharmacogenetic Testing in Asthma$129,060
K08 · FY2011 · HL · contact PI
Effectiveness of Pharmacogenetic Testing in Asthma$128,940
K08 · FY2010 · HL · contact PI
Effectiveness of Pharmacogenetic Testing in Asthma$128,772
K08 · FY2009 · HL · contact PI